$ABVX News

Last published 1w ago

1w agoABVXAbivax to Participate in Upcoming Fall Investor ConferencesGlobeNewswireAbivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage
1mo agoABVXAbivax Presents Business Updates and First Half 2026 Financial ResultsGlobeNewswireAbivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness
3mo agoABVXAbivax Announces Positive Pre-NDA Interaction with the FDA for ObefazimodGlobeNewswireAbivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative
3mo agoABVXAbivax Strengthens Commercial Capabilities With Strategic Leadership AppointmentsGlobeNewswireAbivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force
4mo agoABVXAbivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCCNBCIts latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
4mo agoABVXAbivax Announces Closing of $920 Million Public OfferingGlobeNewswireAbivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology
4mo agoABVXAbivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)GlobeNewswireAbivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX)
4mo agoABVXCorrection: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesGlobeNewswireAbivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS,
4mo agoABVXAbivax announces trading resumption of its ordinary shares on Euronext ParisGlobeNewswireAbivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage
4mo agoABVXAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesGlobeNewswireAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a
4mo agoABVXAbivax announces temporary trading halt of its ordinary shares on Euronext ParisGlobeNewswireAbivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage
4mo agoABVXAbivax Announces Launch of Public Offering of American Depositary SharesGlobeNewswireAbivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage
4mo agoABVXFrench biotech stock soars 25% after new data on experimental medicineCNBCShares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
4mo agoABVXAbivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety DatabaseGlobeNewswire
5mo agoABVXAbivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)PR NewswireAbivax (NASDAQ: ABVX) shareholders more than to 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of...
5mo agoABVXBiotech takeover target Abivax sinks over 30% after bowel disease drug trial updateCNBCShares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
5mo agoABVXABTECT MAINTENANCE RESULTS INVESTOR WEBCAST - ABTECTEarnings Call TranscriptsGood afternoon and good evening, everyone. We hope you've had a chance to review the press release we issued after market closed in the U.S. today, announcing the positive top-line results of the Phase 3 Abtec Maintenanc
5mo agoABVXAbivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisGlobeNewswireAbivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the
5mo agoABVX ORKA SYREPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationGlobeNewswireDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech
5mo agoABVXAbivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative ColitisGlobeNewswireAbivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative
6mo agoABVXAbivax Announces Results of its May 11, 2026 Annual General MeetingGlobeNewswireAbivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company
6mo agoABVXAbivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary SharesGlobeNewswireAbivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Cash runway remains into Q4 2027, supporting continued funding of clinical programs and
6mo agoABVXAbivax to Present Data on Obefazimod at Digestive Disease Week®GlobeNewswireAbivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic
6mo agoABVXAbivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory DocumentsGlobeNewswireAbivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or
7mo agoABVXAbivax Publishes Financial Reports with the French and U.S. Securities Regulatory AgenciesGlobeNewswireAbivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 –
7mo agoABVXAbivax Announces Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireAbivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of
8mo agoABVXAbivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026GlobeNewswireAbivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn's and
10mo agoABVXAbivax Provides 2026 Corporate OutlookGlobeNewswireAbivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD
10mo agoABVX NBIAbivax to be Added to Nasdaq Biotechnology IndexGlobeNewswireAbivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on
10mo agoABVXAbivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic FindingsGlobeNewswireAbivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The
11mo agoABVXAbivax Presents Third Quarter 2025 Financial ResultsGlobeNewswireAbivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA
1y agoABVXAbivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative ColitisGlobeNewswireAbivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative
1y agoABVXAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced TherapiesGlobeNewswireAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved
1y agoABVXAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety DataGlobeNewswireAbivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at
1y agoABVXAbivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) MeetingGlobeNewswireAbivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND
1y agoABVXAbivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) MeetingGlobeNewswireAbivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD
1y agoABVXAbivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewGlobeNewswireAbivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology
1y agoABVXAbivax Presents First Half 2025 Financial ResultsGlobeNewswireAbivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing
1y agoABVXAbivax Announces Closing of $747.5 Million Public OfferingGlobeNewswireAbivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on
1y agoABVXAbivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)GlobeNewswireAbivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (PARIS:FR)
1y agoABVXAbivax announces trading resumption of its ordinary shares on Euronext ParisGlobeNewswireAbivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company
1y agoABVXAbivax Announces Pricing of $650M (€554M) Public Offering of American Depositary SharesGlobeNewswireAbivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology
1y agoABVXAbivax announces temporary trading halt of its ordinary shares on Euronext ParisGlobeNewswireAbivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology
1y agoABVXAbivax Announces Launch of Public OfferingGlobeNewswireAbivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics
1y agoABVXAbivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative ColitisGlobeNewswireAbivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily
1y agoABVXAbivax Announces Results of its June 6, 2025 Annual General MeetingGlobeNewswireAbivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on
1y agoABVXAbivax Presents First Quarter 2025 Financial ResultsGlobeNewswireAbivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing
1y agoABVXAbivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative ColitisGlobeNewswireAbivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in
1y agoABVXAbivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving MilestonesGlobeNewswireAbivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials
1y agoABVXAbivax Announces Appointment of Dominik Höchli, MD to Board of DirectorsGlobeNewswireAbivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France,